摘要
目的:探讨来得时(甘精胰岛素)联合诺和锐(门冬胰岛素)治疗T2DM患者的疗效及安全性。方法:将40例口服降糖药疗效差的2型糖尿病患者随机分为两组,每组20例,来得时组采用三餐时注射诺和锐,每晚九点注射来得时;诺和灵组采用三餐前30 min皮下注射诺和灵R,每晚十点注射诺和灵N,3个月后观察记录各项指标的变化情况。结果:两组治疗后,FBG、2 hPG、HbA1c均显著下降(P<0.05),FC-P、2 hC-P均显著升高(P<0.05);来得时组血糖达标时间明显缩短(P<0.01)。两组均未发生严重低血糖事件,来得时组发生低血糖次数、夜间低血糖次数均显著减少(P<0.01)。结论:来得时联合诺和锐治疗2型糖尿病更具有效性和安全性。
Objective： To discuss the therapeutic effect and safety of Lantus combined with Novorapid in the treatment of patients with type 2 diabetes.Methods： 40 cases of type 2 diabetes were randomly divided into group A and group B,each group with 20 cases.Novorapid before each meal and bedtime Lantus（group A） versus novolin R before each meal and bedtime novolin N（group B） on patients with type 2 diabetes.After the three months treatment,glucose-targeted time（GTT）,FBG,2 hPG,glucose drift and hypoglycemic frequency were compared.Results： Group A and group B had dropped on FBG,2 hPG and HbA1c（P〈0.05）,and had risen on FC-P and 2 hC-P（P〈0.05）.But group A showed more rapid and sta-ble effect in lowering blood sugar than group B（P〈0.01）,and GTT was shorter.Conclusion： For type 2 diabetes patients,Lantus and Novorapid have better therapeutic effects and lower hypoglycemic frequency.
出处
《中国医药导报》
CAS
2010年第32期65-66,共2页
China Medical Herald
